Immuneering Corp (IMRX): R&D Expense
$42.05M
Year ended 2025-12-31
$44.76M
Trailing 12 months to 2026-06-30
+5.1%
3-year compound annual growth
+22.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $42.05M | -12.3% | 2026-03-06, From 2025-01-01 |
| 2024-12-31 | $47.96M | +15.2% | 2026-03-06, From 2024-01-01 |
| 2023-12-31 | $41.62M | +14.8% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $36.27M | +36.6% | 2024-03-01, From 2022-01-01 |
| 2021-12-31 | $26.54M | +76.9% | 2023-03-06, From 2021-01-01 |
| 2020-12-31 | $15.00M | n/a | 2022-03-10, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Immuneering Corp (IMRX) | 2025-12-31 | $42.05M | -12.3% |
| Oramed Pharmaceuticals Inc. (ORMP) | 2025-12-31 | $6.38M | +0.9% |
| Design Therapeutics, Inc. (DSGN) | 2025-12-31 | $59.13M | +33.3% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $9.58M | +4.4% |
| Pliant Therapeutics, Inc. (PLRX) | 2025-12-31 | $109.16M | -35.5% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $74.04M | +15.3% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $8.26M | -3.7% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $138.09M | +868.4% |
| Abeona Therapeutics Inc. (ABEO) | 2025-12-31 | $26.81M | -22.0% |
Compare IMRX, ORMP, DSGN, EOLS side by side · Screen every company in Pharmaceutical Preparations ↗